ICAP, Mailman School of Public Health, Columbia University, New York, NY, USA.
J Acquir Immune Defic Syndr. 2012 Aug 15;60 Suppl 3(Suppl 3):S105-12. doi: 10.1097/QAI.0b013e31825cf4f5.
HIV/AIDS has had a profound impact on children around the world since the start of the epidemic. There are currently 3.4 million children under the age of 15 years living with HIV globally, and more than 450,000 children currently receiving lifesaving antiretroviral treatment. This article describes efforts supported by the President's Emergency Plan for AIDS Relief (PEPFAR) to expand access to treatment for children living with HIV in high-burden countries. The article also highlights a series of case studies that illustrate the impact that the PEPFAR initiative has had on the pediatric HIV epidemic. Through its support of host governments and partner organizations, the PEPFAR initiative has expanded HIV testing and treatment for pregnant women to reduce vertical transmission of HIV, increased access to early infant diagnosis for HIV-exposed infants, improved training and resources for clinicians who provide pediatric care and antiretroviral treatment, and, through public-private partnerships with pharmaceutical manufacturers, helped increase the number of medications available for the treatment of HIV-infected children in resource-limited settings.
自艾滋病疫情开始以来，艾滋病毒/艾滋病对全球儿童产生了深远的影响。目前，全球有 340 万 15 岁以下的儿童携带艾滋病毒，目前有超过 45 万名儿童正在接受救命的抗逆转录病毒治疗。本文介绍了“总统艾滋病紧急救援计划”（PEPFAR）支持的努力，以扩大在高负担国家中艾滋病毒感染儿童获得治疗的机会。本文还重点介绍了一系列案例研究，说明 PEPFAR 倡议对儿科艾滋病毒流行的影响。通过支持所在国政府和伙伴组织，PEPFAR 倡议扩大了艾滋病毒检测和治疗范围，以减少艾滋病毒母婴垂直传播，增加了艾滋病毒暴露婴儿的早期诊断机会，改善了为儿科护理和抗逆转录病毒治疗提供服务的临床医生的培训和资源，并通过与制药商的公私伙伴关系，帮助增加了在资源有限的环境中治疗艾滋病毒感染儿童的药物数量。
